A novel approach has been developed to synthesize magnetic nanoparticle and carbon nanotube (CNT) core-shell nanostructures, such as CoO/CNTs and Mn(3)O(4)/CNTs, by the nonaqueous solvothermal treatment of metal carbonyl on CNT templates using hexane as the solvent. The morphological and structural characterizations indicate that numerous cubic CoO or tetragonal Mn(3)O(4) nanoparticles are deposited on the surfaces of the CNTs to form CNT-based core-shell nanostructures. It is revealed that the hydrophobic interaction between nanoparticles and CNTs in hexane plays the critical role for the formation of CNT-based core-shell nanostructures. A physical property measurement system (PPMS-9, Quantum Design) analysis indicates that the CoO/CNT core-shell nanostructures show weak ferromagnetic performance at 300 K due to the ferromagnetic Co clusters and the uncompensated surface spin states, while the Mn(3)O(4)/CNT core-shell nanostructures display ferromagnetic behavior at low temperature (34.5 K), which transforms into paramagnetic behavior with increasing temperature.

Objective. To investigate hypoxia-induced Nestin regulates lung cancer viability and metabolism by targeting transcription factors Nrf2, STAT3, and SOX2. Methods. Eighty-four cases of nonsmall cell lung cancer (nonsmall cell lung cancer, NSCLC), which had been treated from June 2020 to February 2021, were randomly selected from our clinicopathology database. Immunohistochemical staining of collected tissue cells was performed to assess the expression patterns of Nestin, STAT3, Nrf2, and SOX2. Data were quantified and statistically analyzed using one-way and two-way ANOVA tests with . Results. Clinicopathological findings showed significant differences in lymph node metastasis, tissue differentiation, and histology on induction of Nestin expression; Nestin expression correlated with STAT3, Nrf2, and SOX2 expression.Nestin/STAT3/SOX2/Nrf2 are involved in angiogenesis and lung cancer development. Conclusion. Hypoxia-induced Nestin promotes the progression of nonsmall lung cancer cells by targeting the downstream transcription factors STAT3, Nrf2, and SOX2.